Department of General Surgical Science, Gunma University Graduate School of Medicine, Maebashi, Japan
Department of Innovative Cancer Immunotherapy, Gunma University Graduate School of Medicine, Maebashi, Japan
Anticancer Res. 2019 Aug;39(8):4111-4116. doi: 10.21873/anticanres.13569.
BACKGROUND/AIM: We investigated whether the expression of inositol 1, 4, 5-trisphosphate receptor-binding protein released with inositol 1, 4, 5-trisphosphate (IRBIT) in clinical gastric cancer (GC) patients could predict the therapeutic response to postoperative adjuvant chemotherapy.
Immunohistochemistry was used to investigate IRBIT expression in 115 GC patients. To clarify whether IRBIT had a relationship with the therapeutic effects of chemotherapy, we compared two groups - 62 patients treated with postoperative adjuvant chemotherapy and 53 patients treated with postoperative adjuvant chemotherapy.
Regarding the postoperative adjuvant chemotherapy-free group, we did not find any statistically significant correlation between clinicopathological features and recurrence regardless of the expression of IRBIT. In contrast, in the group receiving postoperative adjuvant chemotherapy, a significant association was found between IRBIT expression and both overall and disease-free survival.
IRBIT may be used as a useful predictive marker for chemotherapy.
背景/目的：我们研究了在临床胃癌（GC）患者中，与三磷酸肌醇（IP3）结合的肌醇 1,4,5-三磷酸受体结合蛋白（IRBIT）的表达是否可以预测术后辅助化疗的治疗反应。
免疫组织化学法检测了 115 例 GC 患者的 IRBIT 表达。为了阐明 IRBIT 是否与化疗的治疗效果有关，我们比较了两组患者——62 例接受术后辅助化疗的患者和 53 例接受术后辅助化疗的患者。
关于术后无辅助化疗组，无论 IRBIT 的表达如何，我们都没有发现其与临床病理特征和复发之间存在任何统计学显著相关性。相比之下，在接受术后辅助化疗的组中，IRBIT 表达与总生存期和无病生存期均存在显著相关性。
IRBIT 可作为化疗的有用预测标志物。
